Compare · DVAX vs PFE
DVAX vs PFE
Side-by-side comparison of Dynavax Technologies Corporation (DVAX) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVAX and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $150.91B, about 99.8x DVAX ($1.51B).
- Over the past year, DVAX is up 59.7% and PFE is up 16.3% - DVAX leads by 43.4 points.
- PFE has hit the wire 27 times in the past 4 weeks while DVAX has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 8 for DVAX).
- Company
- Dynavax Technologies Corporation
- Pfizer Inc.
- Price
- $15.49+0.00%
- $26.50+0.23%
- Market cap
- $1.51B
- $150.91B
- 1M return
- +0.55%
- -2.29%
- 1Y return
- +59.74%
- +16.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 0
- 27
- Recent ratings
- 8
- 25
Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest DVAX
- SEC Form 15-12G filed by Dynavax Technologies Corporation
- SEC Form EFFECT filed by Dynavax Technologies Corporation
- SEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
Latest PFE
- SEC Form S-8 filed by Pfizer Inc.
- SEC Form 10-Q filed by Pfizer Inc.
- Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
- Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
- Pfizer Reaches Three Settlement Agreements for VYNDAMAX
- SEC Form 4 filed by Director Nora Johnson Suzanne M
- SEC Form 4 filed by Director Littman Dan R.